



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ni *et al.*

Appl. No.: 10/648,825

Filed: August 27, 2003

For: **Death Domain Containing
Receptor-5 Antibodies and
Methods of Use (As Amended)**

Confirmation No.: 3624

Art Unit: 1646

Examiner: Kaufman, Claire M.

Atty. Docket: 1488.131000C/EJH/SAC

Eleventh Supplemental Information Disclosure Statement

Filing under 37 C.F.R. § 1.97(c).

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Eleventh Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Tenth Information Disclosure Statement filed on December 6, 2006 in connection with the above-captioned application.

Copies of **AO5**, and **AR72** to **AR82** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent publications, documents **AB5** to **AC5** cited on the attached IDS Form PTO/SB/08A, are not submitted.

In addition, the Examiner's attention is directed to the following Interference Nos. 105,361; 105,240; 105,380 and 105,381 which are directed to related subject matter. Applicants have cited patents, patent applications, and non-patent references listed in the

10/10/2006 09:00:00 AM 10/10/2006

10/10/2006

10/10/2006

Exhibit Lists for Interference Nos. 105,361; 105,240; 105,380 and 105,381 that have not already been made of record in the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants' would like to bring to the attention of the Examiner that, for the following document, the publication month could not be determined to the best of the Applicants' ability: **AT72**, Naismith, J.H., *et al.*, "Tumor Necrosis Factor Receptor Superfamily," *J. Inflammation* 47:1-7, Wiley-Liss, Inc. (1996). Applicants believe that the document was published in the beginning of 1996 but could not determine the exact month of publication.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: December 19, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

618013v1



Equivalent of Form PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**~~CONFIDENTIAL~~ FIFTEENTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/648,825
Filing Date	August 27, 2003
First Named Inventor	Jian Ni
Art Unit	1646
Examiner Name	Kaufman, Claire M.
Attorney Docket Number	1488.131000C/EJH/SAC

U.S. PATENT DOCUMENTS

[illegible]


622094v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Application Number</i>	10/648,825
				<i>Filing Date</i>	August 27, 2003
				<i>First Named Inventor</i>	Jian Ni
				<i>Art Unit</i>	1646
				<i>Examiner Name</i>	Kaufman, Claire M.
Sheet	1	of	4	<i>Attorney Docket Number</i>	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR72	Liu, Z.G., <i>et al.</i> , "Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF- κ B Activation Prevents Cell Death," <i>Cell</i> 87:565-576, Cell Press (November 1996)	
	AS72	Johnson, N.L., <i>et al.</i> , "Signal Transduction Pathways Regulated by Mitogen-activated/Extracellular Response Kinase Kinase Kinase Induce Cell Death," <i>J Biol. Chem.</i> 271:3229-3237, The American Society for Biochemistry and Molecular Biology (February 1996)	
	AT72	Naismith, J.H., <i>et al.</i> , "Tumor Necrosis Factor Receptor Superfamily," <i>J. Inflammation</i> 47:1-7, Wiley-Liss, Inc. (1996)	
	AR73	Mackey, F., <i>et al.</i> , "Lymphotoxin β Receptor Triggering Induces Activation of the Nuclear Factor κ B Transcription Factor in Some Cell Types," <i>J. Biol. Chem.</i> 271:24934-24938, The American Society for Biochemistry and Molecular Biology, Inc. (October 1996)	
	AS73	Rennert, P.D., <i>et al.</i> , "Surface Lymphotoxin α/β Complex Is Required for the Development of Peripheral Lymphoid Organs," <i>J. Exp. Med.</i> 184:1999-2006, The Rockefeller University Press (November 1996)	
	AT73	Eischen, C.M., <i>et al.</i> , "Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions," <i>Blood</i> 90:935-943, The American Society of Hematology (August 1997)	
	AR74	Chapman, B.S., "A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-1 and Fas," <i>FEBS Lett</i> 374:216-220, Elsevier Science Ltd. (1995)	
	AS74	Beg, A.A. and Baltimore, D., "An Essential Role for NF- κ B in Preventing TNF- α -Induced Cell Death," <i>Science</i> 274:782-784, American Association for the Advancement of Science (November 1996)	
	AT74	Van Antwerp, D.J., <i>et al.</i> , "Suppression of TNF- α -Induced Apoptosis by NF- κ B," <i>Science</i> 274:787-789, American Association for the Advancement of Science (November 1996)	
	AR75	Wang, C.-Y., <i>et al.</i> , "TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF- κ B," <i>Science</i> 274:784-787, American Association for the Advancement of Science (November 1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Jian Ni
				Art Unit	1646
				Examiner Name	Kaufman, Claire M.
Sheet	2	of	4	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AS75	Hess, S. and Engelmann, H., "A Novel Function of CD40: Induction of Cell Death in Transformed Cells," <i>J. Exp. Med.</i> 183:159-167, The Rockefeller University Press (January 1996)	
	AT75	Sato, T., <i>et al.</i> , "A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40," <i>FEBS Lett.</i> 358:113-118, Elsevier Science Ltd. (1995)	
	AR76	Liu, Y.-J., <i>et al.</i> , "Mechanism of antigen-driven selection in germinal centres," <i>Nature</i> 342:929-931, Nature Publishing Company (1989)	
	AS76	Tsubata, T., <i>et al.</i> , "B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40," <i>Nature</i> 364:645-648, Nature Publishing Company (1993)	
	AT76	Hsu, <i>et al.</i> , "The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF- κ B Activation," <i>Cell</i> 81:495-504, Cell Press (1995)	
	AR77	Reed, J.C., "Mechanisms of Apoptosis," <i>Am. J. Pathol.</i> 157:1415-1430, American Society for Investigative Pathology (November 2000)	
	AS77	Doctor, K.S., <i>et al.</i> , "The apoptosis database," <i>Cell Death Different.</i> 10:621-633, Nature Publishing Group (June 2003)	
	AT77	Reed, J.C., <i>et al.</i> , "The Domains of Apoptosis: A Genomics Perspective," <i>Sci. STKE</i> re9:1-29, American Association for the Advancement of Science (June 2004)	
	AR78	Copy of U.S. Application No. 09/378,045, inventor Rauch, C., filed August 20, 1999 (NOT PUBLISHED)	
	AS78	Dempsey, P.W., <i>et al.</i> , "The signaling adaptors and pathways activated by TNF superfamily," <i>Cytokine Growth Rev.</i> 14:193-209, Elsevier Science Ltd. (June-August 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Jian Ni
				Art Unit	1646
				Examiner Name	Kaufman, Claire M.
Sheet	3	of	4	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AT78	Headon, D.J., <i>et al.</i> , "Gene defect in ectodermal dysplasia implicates a death domain adapter in development," <i>Nature</i> 414:913-916, Nature Publishing Company (December 2001)	
	AR79	Bridgham, J.T., <i>et al.</i> , "All in the family: evolutionary and functional relationships among death receptors," <i>Cell Death Different.</i> 10:19-25, Nature Publishing Company (January 2003)	
	AS79	Pawlowski, K., <i>et al.</i> , "From fold to function predictions: an apoptosis regulator protein BID," <i>Comp. Chem.</i> 24:511-517, Elsevier Science Ltd. (May 2000)	
	AT79	Jang, Y.-J., <i>et al.</i> , "Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities," <i>Cancer Lett.</i> 194:107-117, Elsevier Science Ltd. (May 2003)	
	AR80	Daniels, R.A., <i>et al.</i> , "Expression of TRAIL and TRAIL receptors in normal and malignant tissues," <i>Cell Res.</i> 15:430-438, Institute of Biochemistry and Cell Biology (June 2005)	
	AS80	Gong, B. and Almasan, A., "Apo2 Ligand/TNF-related Apoptosis-inducing Ligand and Death Receptor 5 Mediate the Apoptotic Signaling Induced by Ionizing Radiation in Leukemic Cells," <i>Canc. Res.</i> 60:5754-5760, American Association for cancer Research (October 2000)	
	AT80	Yun, T.J., <i>et al.</i> , "OPG/FDCR-1, a TNF Receptor Family Member, Is Expressed in Lymphoid Cells and Is Up-regulated by Ligating CD40," <i>J. Immunol.</i> 161:6113-6121, American Association of Immunologists (December 1998)	
	AR81	Screaton, G.R., <i>et al.</i> , "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," <i>Curr. Biol.</i> 7:693-696, Current Biology Ltd. (September 1997)	
	AS81	Clancy, L., <i>et al.</i> , "Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 102:18099-18104, National Academy of Sciences (December 2005)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger
Judith U. Kim
Patrick E. Garrett

Jeffrey T. Helvey
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Mark Fox Evens
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht

Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Young Tang

Christopher J. Walsh
W. Blake Coblenz*
James J. Pohl*
John T. Haran
Mark W. Rygiel
Kevin W. McCabe
Michael R. Malek*
Doyle A. Siever*
Ulrike Winkler*

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

December 19, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8822

INTERNET ADDRESS:
SCARROLL@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1646
Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/648,825; Filed: August 27, 2003
For: **Death Domain Containing Receptor-5 Antibodies and Methods of Use**
(As Amended)
Inventors: Ni *et al.*
Our Ref: 1488.131000C/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of **\$180.00** to cover the IDS fee;
2. Eleventh Supplemental Information Disclosure Statement Filing under 37 C.F.R. §1.97(c);
3. Form PTO/SB/08A (1 page) listing three (3) cited documents (**AB5, AC5 and AO5**);
4. Form PTO/SB/08B (4 pages) listing **31** cited documents (**AR72-AR82**);
5. Copies of **32** cited documents (**AO5 and AR72-AR82**); and
6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 19, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in cursive script, reading "Shannon A. Carroll".

Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

EJH/SAC:kim
Enclosures
622165_1.DOC